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Abstract:
Background:
Though often perceived as a “silver bullet” treatment for bipolar disorder (BD), lithium has seldom reported to lose its efficacy over
the time.
Objective:
The aim of the present study was to assess cases of refractoriness toward restarted lithium in BD patients who failed to preserve
maintenance.
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Method:
Treatment  trajectories  associated  with  re-instituted  lithium  following  loss  of  achieved  lithium-based  maintenance  in  BD  were
retrospectively reviewed for 37 BD-I patients (median age 52 years; F:M=17:20 or 46% of the total) over an 8.1-month period on
average.
Results:
In  our  sample  only  4  cases  (roughly  11%  of  the  total,  of  whom  F:M=2:2)  developed  refractoriness  towards  lithium  after  its
discontinuation.  Thirty-three  controls  (F:M=15:18)  maintained  lithium  response  at  the  time  of  re-institution.  No  statistically
significant difference between cases and controls was observed with respect to a number of demographic and clinical features but for
time spent before first trial ever with lithium in life (8.5 vs. 3 years; U=24.5, Z=-2.048, p=.041) and length of lithium discontinuation
until  new therapeutic attempt (5.5 vs.  2  years;  U=8,  Z=-2.927,  p=.003) between cases vs.  controls  respectively.  Tapering off  of
lithium was significantly faster among cases vs. controls (1 vs. 7 days; U=22, Z=-2.187), though both subgroups had worrisome high
rates of poor adherence overall.
Conclusion:
Although intrinsic limitations of the present preliminary assessment hamper the validity and generalizability of overall results, stating
the clinical relevance of the topic further prospective research is warranted. The eventual occurrence of lithium refractoriness may
indeed be associated with peculiar course trajectories and therapeutic outcomes ultimately urging the prescribing clinicians to put
efforts in preserving maintenance of BD in the absence of any conclusive research insight on the matter.
Keywords: Discontinuation, Maintenance, Refractoriness, Tolerance.
1. INTRODUCTION
In  folklore,  a  bullet  cast  from  silver  is  often  considered  as  the  ultimate  weapon  with  unparalleled  ballistics
performances against a werewolf, witch, or other “beasts”. As a precious good, a “silver bullet” should be handled with
care [1].
To some extent, lithium is often perceived as a “silver” or “magic bullet” by many prescribing clinicians or patients
[2, 3], especially in the prophylaxis of manic  recurrence associated  to the “classical” forms of bipolar  disorder (BD)
[4, 5].
While lithium remains the gold standard in the maintenance treatment of bipolar disorders, valproate, olanzapine,
lamotrigine, aripiprazole, and quetiapine have been shown efficacious for this indication, with quetiapine possessing the
broadest approval status of all drugs for the different treatment phases of this illness. Despite this progress there remains
a huge demand regarding new compounds for nearly every area in the psychopharmacological treatment of bipolar
disorders.  In  addition,  new methodological  approaches  regarding  the  proof  of  effectiveness  in  clinical  practice  are
urgently needed [6], last but not least, with a special reference about the much controversial occurrence of a transient
effectiveness of lithium  even in those cases who  originally achieved  maintenance while exposed (also)  to such drug
[7 - 9].
Indeed, as a “silver bullet” may lose its shine over the time, lithium could likewise lose effectiveness upon achieved
maintenance of BD, either due to “pharmacodynamics tolerance” (hereinafter just referred to as “tolerance”) or via
“discontinuation-induced refractoriness” (“DIR”), or so it has been seldom postulated by some [9, 10].
While  there  is  converging  evidence  pointing  out  the  increased  risk  for  relapse,  affective  psychosis  and  suicide
following lithium discontinuation, especially in case of rapid down-titration even after many years of clinical stability of
BD [11 - 16], such risk is not fully accounted by the natural course of BD [17, 18].
Neither,  conclusive  evidence  exists  about  the  actual  occurrence  of  loss  of  lithium prophylaxis  and/or  enduring
response over the time [9, 19].
Both tolerance and DIR may represent relatively infrequent outcomes, with documented point-prevalence being in
the 5-10% range [9, 10]. Also, patterns of lithium response may sensibly vary across the individual patients [20, 21],
further hindering assessment of the matter even when adopting life-charting approach [22 - 24].
Corresponding  evidence  is  substantially  anecdotal  and/or  possibly  hampered  by  inconsistency  of  the  adopted
operational definitions, optimal average lithium levels, and heterogeneity of the research settings [7, 8, 10, 19, 25 - 28].
Anyway, stating the considerable risk associated with relapse of BD, further assessment about the actual occurrence
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of  DIR and tolerance phenomena is  warranted,  even at  a  case-series  or  selective chart-review level  [10],  as  it  may
eventually parallel the much worrisome neuroprogression of BD [29, 30] irrespective to the efforts ideally [31] put in
the integration of psychoeducation [32] and optimized personalized treatment to pursue and preserve maintenance of
BD [33].
Regrettably,  even  bipolar  patients  who  eventually  achieve  maintenance  may  stop  their  lithium  for  a  variety  of
reasons [34], despite a number of effective strategies to manage its potentially burdensome side-effect profile [35] and
uncertainty still surrounding the effectiveness of lithium alternatives, with the notable exception of valproate or possibly
carbamazepine [36 - 39].
Therefore, stating both the clinical relevance and the debated nature of the topic, we hypothesized that additional
insight would be needed to assess the eventual phenomena associated to loss of lithium response over the time, if ever
occurring.
Thus,  the  aim of  the  present  preliminary study was to  assess  the  clinical  features  eventually  associated to  such
potential  outcome(s),  based  on  hierarchical  clinical  parameters  and  moderators  already  outlined  in  the  scarce  and
inconsistent literature reported on the matter.
2. METHOD
2.1. Sample
A convenience sample of treatment-seeking patients admitted to two outpatient facilities in Italy (Genoa and Pisa)
between April 2008 and June 2016 was retrospectively reviewed. Either self-referrals or those cases referred by their
primary care physician were evaluated. Participants were adults aged 18-65 years, both sexes, with a primary diagnosis
of BD either Type-I (BD-I), Type-II (BD-II), or not otherwise specified (BD-NOS) according to the Diagnostic and
Statistical Manual for Mental Disorders, Fourth Edition (DSM-IV) criteria [40]. Eligible patients were those who failed
to preserve achieved long-term lithium-based maintenance of BD. These later patients would include either i) cases who
stopped lithium (any reason) before loss of maintenance (some of whom would then possibly had developed DIR); ii)
cases who continued their lithium medication at the same, clinically valid, blood levels of the drug at the time they
nonetheless lost maintenance (some of whom would have then eventually developed tolerance towards lithium). All
eligible patients were then “exposed” to “restarted treatment with lithium” (at clinically valid doses equal or higher than
the  ones  proven  effective  at  the  time  of  maintenance,  still  in  the  absence  of  hypothyroidism  or  other  clinical
confounding factors). Those patients who failed to respond at least once more toward restarted lithium were labeled as
“cases” (either due to DIR or tolerance) in contrast to those who responded at least once again toward lithium following
its discontinuation upon achieved maintenance of BD “controls”, actually being those subjects without the “condition at
interest”  for  the  present  study:  “refractoriness/loss  of  lithium  response  towards  restarted  treatment  with  lithium
following  loss  of  maintenance”.  Controls  were  matched  based  only  on  the  diagnostic  Type  of  BD  (diagnosis  last
vouched at the time of loss of long-term maintenance) in order to avoid “over-matching”.
Patients  excluded in  the  present  chart  review were either:  i)  pregnant  women or  those at  childbearing potential
refusing to take a valid anticonception tool (as this cohort could not have been “exposed” to lithium; ii) patients with
severe  cognitive  impairment;  iii)  patients  with  known  history  of  poor  treatment-adherence  based  on  the
clinician’/caregivers’ judgment; iv) patients who failed to undertake regular [41] lab screening of lithium blood levels,
thyroid and kidney functioning; v) subjects refusing to provide a valid signed consent (actually, n=4, due to privacy
concerns). Thus, a total of 37 out of 41 (90.24%) unique clinical records met our inclusion criteria.
2.2. Procedure
Relevant demographic, clinical, and treatment information (including lifetime non-pharmacological treatment self-
reported by the patient)  were recorded by a clinical  investigator abstractor blind to the study hypothesis (PF) upon
receipt  of  a  general  purpose  signed  waiver  obtained  from  each  participating  subject.  Data  were  then  presented
anonymously in an aggregated form using Microsoft Excel [42] to the principal investigator (MF) who reviewed the
information relevant  to  the present  research theme based on a  number of  pre-determined study variables,  owing to
critical methodological considerations for conducting retrospective studies [43, 44].
Specifically, the a priori postulated “study hypothesis” was presence of “cases” (of loss of lithium response upon re-
attempted trial following loss of achieved maintenance of BD) either due to tolerance, DIR, or other/unknown causes.
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Lithium discontinuation or tolerance phenomena at the time of loss maintenance of BD were nonetheless assumed to
potentially occur both among those subjects going to respond once again (“controls”) or the ones actually refractory
toward re-introduced lithium upon its discontinuation (“cases”).
The  main  study  “outcome”  and  “condition  at  interest”  were  the  “response  vs.  refractoriness  toward  restarted
lithium  after  loss  lithium  treatment-based  long-term  maintenance  of  BD”  (thus,  assessing  the  eventual  differential
clinical features associated with “refractoriness vs. response”).
Accounted, eventual, adjunctive treatments to lithium during either the maintenance phase, its subsequent loss, or
the restarted trial attempt with lithium were: U.S. Food and Drug Administration (FDA)-approved drugs for “acute
mania” (& adjunct) and/or “maintenance treatment (of BD)” (and adjunct), depression associated with BD-I (the list of
allowed medications substantially stayed unvaried within the time of most remote vs.  most updated clinical records
within the timeframe of study retrospective follow-up) (www.fda.gov); off-label prescription of most recent second
generation antipsychotics (SGAs), antidepressants, benzodiazepines; or their combination.
An  essential  referenced  summary  of  the  definitions  and  outcomes  adopted  for  the  present  study  is  provided  in
Appendix A.
Finally, upon conception of the study and generation of study’ hypotheses, a clinical scan of the research question
and hypothesis  was  made seeking out  clinical  expertise  with  an  independent  co-author  who assisted  in  the  clinical
interpretation of the results (DDB) and proof-reading alongside with additional co-authors (MS, AV, BS, FI, AC, GP,
ADB).
2.3. Data Analysis
Following dummy coding of the variables at interest (pre-determined) as “yes” =1 or “no” =0, the distribution of
data and the homogeneity of variance were assessed using the Kolmogorov-Smirnov and Levene tests respectively.
Parametric analyses for demographic and clinical characteristics of the groups were performed using the independent-
sample  t-Student  test  for  continuous  variables  (Mann-Whitney-U  (Wilcoxon  rank-sum)  for  non-parametric
distributions)  and  the  Pearson’s  χ2  analysis  (chi-square  goodness-of-fit  test)  for  categorical  variables.  IBM  SPSS
Statistics™ v.22 for Windows [45] was used for statistical analysis, with α=.05, two-tailed.
3. RESULTS
3.1. Overall Clinical Features of the Whole Sample
Median age of reviewed patients was 52 years old (IQR, or inter-quartile range=19), overall median duration in
years (and IQRs) of phases I-, II-, III- and IV- were as follows, respectively: 8.5(6.5), 4(4.25), 5.5(1.75), 1.15(1.43).
Median duration of tapering-off phase, in days, was 1(.75). All patients (F:M=17:20 - 46% of the total) had a diagnosis
of BD-I.
Please refer to Appendix A for additional coding.
None of the patients included in the presented chart-review over a cohort study developed tolerance towards lithium
within  the  retrospectively  assessed  period  of  time.  Only  4  cases  developed  loss  of  lithium  response/lithium-
refractoriness upon its discontinuation (10.8% of the total) in contrast to 33 controls who actually lost maintenance of
BD due to discontinuation occurring for a variety of reasons, yet going to respond once more to re-instituted lithium.
Overall, the included cases and controls were retrospectively assessed for an average period of 8.1 months after loss
of lithium-based maintenance of BD and included only BD-I patients.
A quantitative synthesis of the clinical and demographic features of the patients included in the present study is
presented in Table 1 and Fig. (1) discriminating between cases and controls.
Table 1. Essential demographic and clinical features of the subjects included in the study.
Study subjects
(n=37)
Cases
n=33(89.19% of the total)
Controls
n=4 (10.81% of the total)
χ2(df), t,
or U(Z score)
p
Demographics
Age in years,
median
43 52 166.5, Z=-.01 .915
Sex F/M, n(%) 2(50%)/2(50%) 15(45%)/18(55%) .30(1) .863
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Study subjects
(n=37)
Cases
n=33(89.19% of the total)
Controls
n=4 (10.81% of the total)
χ2(df), t,
or U(Z score)
p
BD-I, n(% - subset) 33(100%) 4(100%) - -
BD-II, n(% - subset) 0 0 - -
BD-NOS, n(% -
subset)
0 0 - -
*Phase-I, length in
years, median
8.5 3 24.5, Z=-2.048 .041
*Phase-II, length in
years, median
4 6 41, Z=-1.234 .217
*Phase-III, length in
years, median
5.5 2 8, Z=-2.927 .003
Pace of lithium
tapering-off, in
days, median
1 7 22, Z=-2.187 .029
*Phase-IV, length in
years among cases,
median
1.15 - - -
Age at onset of BD,
self-report, in years,
median
13 16.5 31, Z=-1.681 .093
Polarity of index
episode, n(% -
subset)
Mania or hypomania,
n=4(100%)
Depression, n=6(18.2%);
mania/hypomania, n=21(63.6%),
Mixed= (18.2%)
2.153(2) .341
#Predominant
polarity, n(% -
subset)
Manic, n=2(50%); depressive,
n=2(50%)
Manic, n=17(51%); depressive,
n=13(39%) n=3(10%) undetermined
.064(1) .801
Reason for loss of
maintenance
(clinician’ judgment
whenever not
otherwise
ascertained), n(% -
subset)
Poor adherence, n=4(100%)
Poor adherence, n=20(61%)
Psoriasis, n=1(3%);
other/undetermined, n=12(36%)
2.429(2) 0.297
Lifetime psychiatric
hospitalization
(“yes”/”no”), n(% -
subset)
1(25%) 5(15%) .255(1) .614
Lifetime PD, n(% -
subset)
0 3(9.13%) .396(1) .529
Lifetime GAD, n(%
- subset)
1(25%) 6(18.2%) .108(1) .742
Lifetime SP, n(% -
subset)
0 1(3%) .125(1) .724
Lifetime OCD, n(%
- subset)
1(25%) 4(12%) .506(1) .477
Lifetime SUD, n(%
- subset)
0 7(21%) 1.046(1) .306
Lifetime AN, n(% -
subset)
0 1(3%) .125(1) .724
Lifetime BN, n(% -
subset)
0 2(6%) .256(1) .613
Lifetime BED, n(%
- subset)
0 1(3%) .125(1) .724
Lifetime ADHD,
n(% - subset)
1(25%) 0 8.479(1) .004
Lifetime Rapid-
cycling course, n(%
- subset)
1(25%) 3(9%) .936(1) .333
Lifetime Seasonal
course, n(% -
subset)
1(25%) 2(6%) 1.718(1) .190
(Table 1) contd.....
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Study subjects
(n=37)
Cases
n=33(89.19% of the total)
Controls
n=4 (10.81% of the total)
χ2(df), t,
or U(Z score)
p
Lifetime Post-
partum depression,
n(% - subset)
0 3(9%) .396(1) .529
Lifetime history of
suicidal ideation
and/or attempt(s),
n(% - subset)
2(50%) 12(36.4%) .282(1) .529
Valproate and/or
carbamazepine
(adjunctive for
phases-II and -IV)
treatment during
Phase-I, -II, -III or -
IV respectively,
n(% - subset)
1(25%)/3(75%)/3(75%)/3(75%) 4(12%)/22(67%)/26(79%)/25(76%) .506(1)/.113(1)/.030(1)/.001(1) .477/.737/.862/.973
SGA(s) (adjunctive
for phases-II and -
IV) treatment
during Phase-I, -II, -
III or -IV
respectively, n(% -
subset)
0/0/1(25%)/3(75%) 2(6%)/2(6%)/2(6%)/18(55%) .256(1)/.256(1)/1.718(1)/.608(1) .613/.613/.190/.435
Antidepressant(s)
(adjunctive for
phases-II and -IV)
treatment during
Phase-I, -II, -III or -
IV respectively,
n(% - subset)
0/0/1(25%)/2(50%) 1(3%)/9(27%)/11(33%)/6(18%) .125(1)/1.442(1)/.113(1)/2.131(1) .724/.230/.737/.144
BDZ (adjunctive for
phases-II and -IV)
treatment during
Phase-I, -II, -III or -
IV respectively,
n(% - subset)
0/1(25%)/3(75%)/4(100%) 11(33%)/10(30%)/12(36%)/19(58%) 1.897(1)/.048(1)/2.209(1)/2.730(1) .168/.827/.137/.276
Adjunctive CBT
during phases-III
n(% - subset)
1(25%) 3(9%) .936(1) .333
§ Lifetime ECT n(%
- subset)
0 0 - -
Legend:  PD=Panic Disorder;  GAD=Generalized Anxiety Disorder;  SP=Specific  Phobias;  OCD=Obsessive-Compulsive Disorder;  ICD=Impulse
Control Disorder; SUD=Substance Use Disorder; AN=Anorexia Nervosa; BN=Bulimia Nervosa; BED=Binge Eating Disorder; ADHD=Attention
Deficit  Hyperactivity  Disorder;  NOS=Not  otherwise  specified;  SGA=Second  Generation  Antipsychotics;  ECT=Electroconvulsive  Therapy;
CBT=Cognitive  Behavioral  Therapy.
Bold p-values indicate significant difference.
* Please refer to Appendix A for additional coding.
#” Predominant polarity” was operationally defined based on Colom F. et al., 2006 [88]. Briefly, “at least 2/3 of lifetime mood episodes overall
experienced as a given mood polarity” would configure either “depressive” or “manic” predominance of overall mood episodes.
§ Cases exposed to lifetime ECT may have gone unrepresented in the present convenience sample since the otherwise clinically relevant practice of
Electroconvulsive Therapy is still relatively infrequently accepted in Italy due to stigma issues [89].
3.2. Comparison of Cases vs. Controls
No  statistically  significant  difference  between  cases  and  controls  was  observed  with  respect  to  a  number  of
demographic and clinical features but for time spent before first trial ever with lithium in life (8.5 vs. 3 years; U=24.5,
Z=-2.048, p=.041) and length of lithium discontinuation until new therapeutic attempt (5.5 vs. 2 years; U=8, Z=-2.927,
p=.003)  between  cases  vs.  controls  respectively.  Tapering  off  of  lithium  was  significantly  faster  among  cases  vs.
controls (1 vs. 7 days; U=22, Z=-2.187), though both subgroups had worrisome high rates of poor adherence overall.
(Table 1) contd.....
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Fig. (1). Median duration of phases I-, II- and III among cases and controls.
4. DISCUSSION
4.1. Main Findings of the Study: Clinical Features Associated to DIR vs. Preserved Response
In our convenience sample, loss of lithium response upon loss of maintenance occurred just in 4 out 41 patients
(roughly 11% of the total). None of the reviewed cases developed tolerance towards lithium. Yet, the infrequency of the
later phenomenon and the unrepresentativeness of the sample size would nonetheless require additional research to
assess whether the prophylactic effect of lithium would be transient or persistent over the time, though reappearance of
affective recurrences after years of successful treatment of BD could not be excluded by supposed persistence of the
prophylactic effects of lithium anyway [7].
There was no statistical difference in the otherwise clinically valid (all in the 0.4-1.1mmol/L range) [46, 47] average
serum level  of  lithium at  the  time  of  last  reliable  assessment  prior  loss  of  maintenance  between  cases  or  controls.
However,  stating  the  recall  bias  and  self-report  assessment  nature  of  the  present  study,  the  related  results  must  be
interpreted with caution, as the actual time between loss of response towards lithium and the measurement of the last
lithium level could not be reliably determined consistently in the preliminary sample in point. Similar considerations
would apply to the statistical difference seen about phase I or ADHD comorbidity (as outlined in Table 1). Neither, a
statistical difference was documented about the most recent levels of triiodothyronine (T3), though the actual validity of
such clinical routine test has been questioned [48, 49].
Too fast tapering of lithium among cases (of whom, one with ascertained attention deficit hyperactivity disorder)
and the median duration of phases -II and -IV were the only statistically different outcomes observed between cases and
controls. Both outcomes have major clinical implications. In our sample, the exposure to antidepressant (adjunctive)
therapy across varying phases was not associated with differential outcomes after lithium trial re-attempt.
Therapeutic outcome upon restart of lithium trial
Cases of lithium refractoriness following 
discontinuation
Controls (preserved lithium response 
following discontinuation)
D
u
ra
ti
o
n
 i
n
 y
ea
rs
12,5
10,0
7,5
5,0
2,5
0,0
Phase_III_duration_in_years
Phase_II_duration_in_years
Phase_I_duration_in_years
Median duration of phases I, II and III in controls and cases
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In this regard, although adjunctive antidepressant treatment for established mood stabilizers has been excluded to be
associated with increased risk for treatment-emergent switch (or antidepressant-efficacy) in BD [50], any conclusive
statement about the actual clinical predictive value of lifetime antidepressant exposure (especially during phases -I or -
III) cannot be made based on the preliminary results from the present study, thus urging for caution and parsimony in
prescription. Moreover, rates of reported loss of maintenance due to poor adherence were strikingly high even among
those patients originally considered as adherent ones, albeit actually taped off their lithium much faster than controls
who  still  allowed  for  few  more  days  on  average.  This  finding  prompts  for  vigilance  and  for  delivery  of  enduring
psychoeducation even after achievement of maintenance of BD, striving at enhancing the tolerability and long-term
management of lithium side-effect profile. In this regard, it is worth notice that lithium was reported less frequently
associated to polypharmacy in BD compared to other medication, whereas polypharmacy is a known contributor for
reduced compliance overall [51]. This later evidence further promotes preservation of lithium whenever possible and
also earlier prescription of lithium in those BD-I patients who would be considered optimal candidates - indeed, in our
sample the average amount of time spent in phase I was much higher among cases vs. controls [52].
According to Kraepelin’s approach, mood disorders are best studied following a longitudinal prospective approach.
Yet,  in  this  case,  we  could  rely  only  on  a  retrospective  approach,  which  further  undermines  the  validity  and
generalizability of our preliminary results based on a small sample size (actually precluding any multivariate analysis or
control  for  any  factor/covariate,  or  any  direct  comparison  of  random-selected  cases  vs.  controls  sharing  common
features).  While  this  later  approach  owed  to  feasibility  considerations,  and  would  be  preferred  to  readily  assess
relatively infrequent outcomes [53], a number of potential biases should nonetheless be considered prior the critical
interpretation  of  the  results  coming  from  the  present  pilot  case-control  over  a  cohort  study.  Among  others,  major
limitations of the present study are due to recall and measurement biases that may have occurred, especially stating the
lack of any clinician-assisted retrospective life-chart measure or external validator of the diagnosis (including biomarker
genetic  or  other  neurobiological  validators),  rating  of  mania/depression/global  assessment  of  BD  or  objective
assessment  of  lithium  adherence  other  than  regular  clinical  lab  testing,  and  lack  of  axis-II  personality  disorder
assessment  (or  demographic  record  about  marital  status  or  education),  despite  the  unquestionable  usefulness  of
graphical charting of mood disorders [54, 55]. Also, the inclusion of a convenience BD-I only sample precluded the
opportunity to readily assess the incidence of new cases of lithium refractoriness, or to compute overall rates of lithium-
discontinuation.  In  addition,  failure  to  achieve  euthymia  upon  an  average  follow-up  of  8.1  months  actually  may
represent  failure  of  acute  treatment  rather  than  failure  to  achieve  maintenance,  further  soliciting  for  more  accurate
prospective  studies.  Similarly,  since  the  sample  at  study  included  only  treatment-seeking  outpatients  rather  than
inpatient admitted to a lithium clinic. While this option gathered some preliminary insight about the outpatient setting, a
Berkson’s  bias  (namely  the  systematic  exclusion  of  most  severe  cases:  indeed  most  patients  self-reported  to  be
substantially  stable  within  phase  II  trial  thus  probably  representing  a  less  severe  subset  of  BD-I  cases)  may  have
likewise  limited  the  generalizability  of  the  present  results  as  the  unrepresentativeness  of  the  control  cases  subset
precluded  any  statistically  meaningful  conclusive  comparison  and  the  lack  of  BD-II  cases  would  have  precluded
additional stratification/correction for multiple comparisons of results based on some otherwise clinically suggestive
predictors of lithium poor adherence and/or refractoriness rather than optimal response, namely, differential sequence of
lifetime mood episodes/predominant polarity, current of lifetime confounding factors (e.g. polypharmacy), presence of
mixed/mood-incongruent psychotic features, cyclothymia and/or lifetime rapid-cycling course, family history for BD,
pyknic body build, and/or presence of psychotic rather than anxious/obsessive traits [30, 47, 56 - 64].
Furthermore, the eventual existence of a “latent time period” related to loss of lithium response [27] would likewise
deserve  additional  investigation,  as  the  present  study  had  not  enough  power  to  assess  this  otherwise  clinically
suggestive  issue,  otherwise  not  necessarily  pertaining  just  to  overt  BD-spectrum  disorders  [65].  Finally,  from  an
epidemiological and neurobiological standpoint, due to the intrinsic limitation of retrospective assessment it cannot be
excluded “reverse causality” of BD-treatment trajectory interplay, as in some cases the disease at issue could cause the
outcome itself [66, 67]. Thus, in the absence of ad-hoc, controlled prospective studies carried across varying clinical
populations, no reliable causal inference could be made about “timing”, “strength of relationship” (in terms of relative
risk), “dose-dependent” relation, or “biological plausibility” about a plethora of pleomorphic phenomena eventually
associated to lithium refractoriness in BD. We therefore propose to re-conceptualize lithium discontinuation- “induced”
refractoriness  (DIR)  into  a  more  prudent  (yet  still  tentative)  evidence-base  sound  “post-discontinuation”  (lithium)
refractoriness”, in line with the findings from a large, prospective naturalistic study by Coryell et al., (1998) which
documented no evidence for reduced lithium prophylactic value after recurrence of mania (or depression) at the time of
resumed treatment with lithium [68]. In addition, even in the presence of refractoriness, inability to make (or exclude)
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any conclusive causal nexus between lithium discontinuation and subsequent loss of response would not per se exclude
the chance of “pseudo”-refractoriness at least in some instances.
While  it  must  be  further  emphasized  that  the  power  of  the  present  pilot  retrospective  study  was  insufficient  to
reliably detect rare and complex outcomes as loss of lithium response over the time may be, it is nonetheless important
to remark the value of lithium, both as a clinical tool and as a research paradigm for a better understanding of “manic-
depressive illness”. The present study included BD-I patients who may have been exposed to the SGA class over the
past decade or so, while previous (post-hoc) prospective reports could not do so owing to publication bias for the SGA
compounds, which have nonetheless been speculated to potentially contribute themselves towards mood stabilization of
BD [69]. Yet, further, large-sampled and rigorous, ad-hoc designed, controlled prospective studies are warranted aiming
at  shedding light  about  the  actual  occurrence of  “loss  of  shine of  the  silver  bullet  over  the  time”.  Current  tentative
evidence  nonetheless  urges  for  caution  in  discontinuing  lithium  as  “valued  goods  should  be  handled  with  care”,
especially  owing  to  a  long-term  perspective  avoiding  too  fast  withdrawal  since  this  later  may  otherwise  trigger
unfavorable epigenetic adaptations [70 - 72] resulting in neuroprogression of BD and increased risk for the associated
much burdensome outcomes of uncontrolled BD, with a special emphasis towards the risk for suicide and other major
personal,  familial  and  social  issues  related  to  BD  progression  and  failure  to  ensure  maintenance,  which  would  go
beyond the single individual to encompass  lithium response across generations  sharing common endo-phenotypes [73,
74], predicting different trajectories towards lithium response [75 - 78].
While there is no consensus about the ideal duration of the maintenance treatment of BD, considering the risk for
recurrence, established international guidelines recommend to continue as long as possible [79 - 81]. In some cases
(patient’  decision,  safety  concerns,  drug  intoxication,  planned  pregnancy)  tapering  off  of  lithium  under  clinician’
guidance despite achieved maintenance of BD, which should be done gradually in order to minimize the risk of relapse,
ideally  over  three  months  or  longer  in  case  of  lithium treatment  [82  -  84]  as  manic  or  hypomanic  rebound  would
otherwise occur in up to 79% of the abrupt withdrawal cases [85].
Please refer to Appendix A for additional coding.
Albeit  with  these  later  reservations,  intrinsic  limitations  of  the  present  study,  and need for  the  identification  of
definite biomarkers of BD progression [86], prudence in discontinuing lithium treatment upon achieved maintenance of
BD  would  therefore  represent  a  primary  goal  both  for  the  clinician,  the  patient  and  his/her  caregivers  striving  at
enhancing safety beyond the sole efficacy, at least in the absence of more conclusive results coming from the above
aimed rigorous, replication studies.
CONCLUSION
Lithium represents the cornerstone treatment of a considerable proportion of bipolar patients. When maintenance is
achieved,  including  lithium  as  part  of  complex  treatment  regimen  (not  necessarily  limited  to  pharmacological
interventions only), that should be preserved balancing the efficacy, safety and tolerability profile for any patient going
to receive long-term or virtually lifetime treatment, especially upon failure with alternative approaches.
Whenever loss of lithium response may occur, attempts should be made to reconstitute its efficacy.
Future,  prospective,  well-designed  studies  should  therefore  shed  further  light  on  the  controversial  issue  of  loss  of
lithium response in bipolar disorder patients who achieved maintenance in the past.
APPENDIX A
Synopsis of the Essential Clinical/Operational Definitions and Outcomes Accounted for the Present Study
Lithium treatment phases  relevant to the operational conceptualization of DIR, based on the operational definitions
outlined by de Vriers C. and colleagues (2013) [19], and the conceptual definitions by Post R. (2012) [9] as follows:
o Phase I: “Pre-lithium phase”. Patients suffer from major mood episodes associated to BD (any polarity), but lithium
treatment has not been started yet.
o Phase II: “Initial lithium treatment phase”. This phase begins when lithium is started (for the first time ever in life),
and ends with its discontinuation, if ever occurring.
o Phase III: It is the “discontinuation” phase: A full stop of lithium medication (usually taking about one-week or so
before  substantial  reduction  of  serum  levels  of  lithium  below  any  clinically  sound  threshold).  Length/pacing  of
Does the “Silver Bullet” Lose its Shine Over the Time? Clinical Practice & Epidemiology in Mental Health, 2016, Volume 12   151
withdrawal (and reasons for) the discontinuation could vary. This phase would last until lithium is eventually restarted
at clinically valid and stable serum levels.
o Phase IV: It is the “reintroduction” period of lithium, for at least three consecutive months at stable and clinically
valid serum levels before assessment of eventual recurrence of a major mood episode - any polarity.
•  Continuation:  According  to  Grunze  H.  et  al.,  2013  [80]  “continuation”  phase  was  considered  as  the  timeframe
following  “remission”  and  preceding  “recovery”.  Continuation  treatment  of  BD would  therefore  aim at  preventing
relapse  into  episode  of  the  same  polarity  of  the  acute  one,  and  the  immediate  switch  to  the  opposite  mood  pole.
Adapting of the medications that  proved to be effective for  the management of  the acute phase (including lithium)
should  be  necessary  before  the  starting  the  long-term  management  of  BD.  Duration  of  the  “post-acute  phase”
continuation  treatment  would  vary  usually  between  4-8  consecutive  weeks.
• Maintenance: Lithium-based  maintenance treatment of BD [71] (either as monotherapy or augmentation therapy)
may onset at any time during the above defined “phase II” trial. Yet, stable and consecutive “euthymia” [90] should be
achieved. Alternative operational definitions of BD remission/euthymia have been outlined by Sussman, N. et al., 2007
[91] as follows: (i) YMRS (Young Mania Rating Scale) [87] score ≤12; (ii) YMRS score ≤12 plus a MADRS score
≤10; (iii) YMRS score ≤12+MADRS score ≤8; (iv) YMRS score ≤8; and (v) YMRS score ≤8 plus a score ≤2 for the
YMRS core items of “Irritability”, “Speech”, “Content”, and “Disruptive/Aggressive Behavior”.
A critical perspective about both clinically meaningful and practical implications of the proposed operational definitions
of maintenance treatment of BD has been outlined by Grunze H. and other members of the WFSBP taskforce (2012),
along with the definition of “continuation” phase [80].
Briefly,  “early  maintenance  treatment  of  BD”  should  prevent  recurrence  of  new  episode(s),  focusing  on  mania,
continuing the medication that treated the acute mood episode (e.g. lithium) over a period of one-year.
“Long-term maintenance treatment of BD” should follow the early maintenance treatment and have a variable length
(ideally, up to life long), focusing on the long-term prevention of depression (or mania).
In  the  present  study,  we  adopted  a  quite  conservative  operational  definition  of  maintenance  (before  lithium
discontinuation),  as  a  period  of  stable  euthymia  lasting  at  least  two  consecutive  years.
•  Prophylaxis:  Prophylaxis  of  BD  would  encompass  both  the  “early”  and  the  “long-term”  maintenance  treatment
phases of BD [80], tough no univocal consensus exists about the pragmatic definition [92].
Note: lithium has been traditionally referred to as a “prophylactic” rather than “maintenance” treatment of BD has it has
historically been considered not effective in the prevention of depressive rather than manic recurrences associated to
BD (a belief later at least partially disproved or questioned sine the pioneer work by Baastrup and Schou) [93].
• Refractoriness: A critical perspective about the concept of (maintenance)-refractoriness in BD has been provided by
Fountoulakis K.N. (2012) [94]. Briefly, since “the terms “refractory” or treatment-resistant is inversely linked to the
term “response”; that is “refractory” are those patients who do not respond”. This general concept best fits MDD rather
than BD, as the latter has a not that linear course neither exacerbations or remissions of a single factor or constellation
of symptoms. Definition of refractoriness in BD is therefore more elusive and should be best conceptualized as patients
“who do fail  to  achieve  (or  restore)  maintenance”,  as  “maintenance”,  rather  than acute  mood-episode remission,
should  be  the  actual  clinically  meaningful  goal  of  BD  treatment.  Similarly,  since  proposed  definition  of  BD
refractoriness based on failure to respond to two or more “adequate” trials of standard classes of antidepressant agents
(6-week  each)  with  or  without  augmentation  strategies  make  poor  clinical  sense  for  BD  as  no  FDA-approved
“antidepressant” drug is also approved for the treatment of bipolar depression (but fluoxetine when combined with the
SGA olanzapine) [95] whereas lithium has negative data with respect to efficacy against bipolar depression [87].
Therefore, we operationally defined DIR as failure to achieve maintenance over a follow-up period not shorter than
nine consecutive weeks (at least once again) following lithium discontinuation.
• Additional definitions of “recurrence”, “relapse”, “remission”, “recovery”, “response” and “roughening” of BD
owed for the present clinically-based study have been summarized by Hirschfeld R.M. et al., 2007 [96].
• Lithium tolerance (pharmacodynamics): Based on the work of Post. R. and his collaborators (2008; 2012) [9, 10],
lithium  refractoriness  may  occur  either  due  to  DIR  or  to  tolerance.  The  two  alternative  scenarios  would  underpin
differential  neurobiological  responses.  Briefly,  in  contrast  to  the  pharmacokinetics  tolerance  phenomenon  possibly
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occurring with opioid medications and other compounds [97], pharmacodynamics tolerance of lithium would occur due
to the eventual progressive emergence of breakthrough mood episodes during long-term prophylactic treatment of BD
(with the same dose of lithium that were originally clinically effective during the maintenance period).
Legend  for  appendix  A:  BD=Bipolar  Disorder;  MDD=Major  Depressive  Disorder;  SGA=Second  Generation
Antipsychotic;  YMRS=Young  Mania  Rating  Scale;  MADRS=Montgomery-Åsberg  Depression  Rating  Scale;
WFSBP=World  Federation  of  Societies  of  Biological  Psychiatry.  DIR=Discontinuation-Induced  [lithium]
refractoriness.
LIST OF ABBREVIATIONS
ADHD = Attention Deficit Hyperactivity Disorder
AN = Anorexia Nervosa
BD-I = Bipolar Disorder Type-I
BD-II = Bipolar Disorder Type-II
BD-NOS = Bipolar Disorder not otherwise specified
BD = Bipolar Disorder
BED = Binge Eating Disorder
BN = Bulimia Nervosa
CBT = Cognitive Behavioral Therapy
DIR = Discontinuation-Induced (lithium) Refractoriness
DSM-IV = Diagnostic and Statistical Manual, Fourth Edition
ECT = Electroconvulsive Therapy
FDA = (U.S.) Food and Drug Administration
GAD = Generalized Anxiety Disorder
ICD = Impulse Control Disorder
IQR = Inter-quartile Range
MADRS = Montgomery-Åsberg Depression Rating Scale
MDD = Major Depressive Disorder
OCD = Obsessive-Compulsive Disorder
PD = Panic Disorder
SD = Standard Deviation
SGA = Second Generation Antipsychotic
SP = Specific Phobias
SUD = Substance Use Disorder
T3 = Triiodothyronine
WFSBP = World Federation of Societies of Biological Psychiatry
YMRS = Young Mania Rating Scale
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